Heparin Market to Reach USD 13.22 Billion by 2030; Increasing Occurrence of Chronic Illnesses Globally to Promote Market Growth

The global heparin market size is anticipated to exhibit strong growth by reaching USD 13.22 billion by 2030. Fortune Business Insights™, in its report, titled, " Heparin Market Size, Share & COVID-19 Impact Analysis, By Product (Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH)), By Source (Bovine and Porcine), By Application (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and Others), By Route of Administration (Intravenous Infusion and Subcutaneous Injection), By End-user (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2023-2030 ” in 2022 and is estimated to reach USD 9.89 billion in 2023. The market is further projected to exhibit a CAGR of 4.2% during 2023 and 2030. Increasing cases of chronic disorders and rising investments in research and development activities are expected to boost the market growth.

Meitheal Pharmaceuticals Announced their Sodium Injection in U.S. to Boost Market Reach

Meitheal Pharmaceuticals launched their novel heparin sodium injection in September 2019 in the U.S. With this launch the company shall satisfy their objective to provide patients with effective medication from safe sources. The product shall enable the company to develop injectable solutions that shall fasten the healing process and boost safety. With this launch, the company shall expand its consumer reach and boost sales. In addition, injectable solutions shall boost the effectiveness of medication and shall enable the company to attract significant demand. 

Reduction in Hospital Visits hinders Sales of these Products

This market is expected to be negatively impacted during the COVID-19 pandemic due to supply issues of essential materials that are required to be sourced from China and a sharp reduction in hospital visits worldwide. Another reason that deters the growth of the market is a strong decline in the number of cardiovascular disease diagnoses and a reduction in hospital visits.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/heparin-market-104447

Rising Cases of Cardiovascular Disorders to Bolster Market Growth

Increasing investments in the development of advanced drugs and medications are likely to fuel market progress. Increasing cases of cardiovascular diseases enable manufacturers to develop effective solutions that mitigate diseases. The rising cases of heart disorders in developing countries such as India are likely to boost product demand drastically. This factor is likely to fuel the demand for the product. Furthermore, technological advancements in the medical sector lead to the development of advanced and effective drugs.

Increasing spending capacity, evolving lifestyle, and rising demand for effective medication is likely to propel the product's sales. These factors are likely to drive the heparin market growth. 

Prominent Companies Launch Novel Products to Improve Brand Image

The prominent companies operating in the market have launched novel products to boost their brand image. For example, Fresenius Kabi presented two presentations of its Sodium in the U.S. in April 2021. The company incorporated the product in ready-to-administer Freeflex IV bags to increase its brand image and boost sales. Further, companies invest heavily in research and development to improve their product quality and improve brand image. In addition, the incorporation of technologically advanced production processes helps companies improve quality, boost operational efficiency, increase revenues and satisfy goals. 

Industry Development

• April 2019: B Braun Medical Inc. launched its novel and first of its kind Sodium Injection with a safety needle for subcutaneous, and intravenous purposes. 

Key Players Profiled in the Market Report

• Opocrin S.p.A. (Italy)


• Baxter (U.S.)


• Pfizer Inc. (U.S.)


• Bioiberica S.A.U. (Spain)


• Fresenius SE & Co. KGaA (Germany)


• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)


• B. Braun SE (Germany)


• Dr. Reddy’s Laboratories Ltd. (India)


• LEO Pharma A/S (Denmark)


• Aspen Holdings (South Africa)


• Sanofi (France)

Further Report Findings-

• The market in North America reached USD 4.87 billion in 2022 and is projected to gain the largest portion of the global heparin market share. The increasing investments in the healthcare sector are likely to boost heparin's adoption. 


• Moreover, evolving consumer preferences and increased medical expenditure boost the product's adoption. Additionally, the presence of major players is expected to boost heparin's adoption. The rising demand for effective medical solutions is expected to bolster industry progress. 


• According to product type (LMWH) is expected to exhibit the highest growth because of the rising adoption of the product in developed markets and the increased adoption of the product compared to other substitutes. These factors are likely to boost market development. 

Table of Segmentation